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Background and Purpose Patients with moyamoya vasculopathy (MMV) may experience cognitive 
impairment, but its reported frequency, severity, and nature vary. In a systematic review and meta-
analysis, we aimed to assess the presence, severity, and nature of cognitive impairments in children 
and adults with MMV. 
Methods We followed the MOOSE guidelines for meta-analysis and systematic reviews of 
observational studies. We searched Ovid Medline and Embase for studies published between 
January 1, 1969 and October 4, 2016. Independent reviewers extracted data for mean intelligence 
quotient (IQ) and standardized z-scores for cognitive tests, and determined percentages of children 
and adults with cognitive deficits, before and after conservative or surgical treatment. We explored 
associations between summary measures of study characteristics and cognitive impairments by 
linear regression analysis. 
Results We included 17 studies (11 studies reporting on 281 children, six on 153 adults). In children, 
the median percentage with impaired cognition was 30% (range, 13% to 67%); median IQ was 98 
(range, 71 to 107). Median z-score was –0.39 for memory, and –0.43 for processing speed. In adults, 
the median percentage with impaired cognition was 31% (range, 0% to 69%); median IQ was 95 
(range, 94 to 99). Median z-scores of cognitive domains were between –0.9 and –0.4, with multiple 
domains being affected. We could not identify determinants of cognitive impairment. 
Conclusions A large proportion of children and adults with MMV have cognitive impairment, with 
modest to large deficits across various cognitive domains. Further studies should investigate 
determinants of cognitive deficits and deterioration, and the influence of revascularization 
treatment on cognitive functioning. 
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Introduction
Moyamoya vasculopathy (MMV) is a cerebrovascular disorder of 
largely unknown etiology characterized by progressive stenosis 
or occlusion of the supraclinoid internal carotid arteries and 
their proximal branches.1,2 Patients may present with transient 
ischemic attacks (TIAs) and ischemic stroke but also with head-
ache, movement disorders, and seizures.1,3 MMV can also lead 
to cognitive impairment.4 Cognitive functions may not only be 
affected by overt or silent brain infarcts or hemorrhages but 
also by chronic hypoperfusion, as cognitive impairment has 
been diagnosed in adults with MMV without stroke.5 Early age 
of onset and longer disease duration have been associated with 
the occurrence of cognitive impairment.6 Many patients with 
MMV undergo surgical revascularization to improve cerebral 
blood flow (CBF) and prevent future ischemic stroke,2 but pro-
spective studies on the effect of surgical treatment on cognition 
are lacking. A previously published descriptive review has pro-
vided an overview on cognition in moyamoya disease (MMD) 
suggesting that the impact of MMV on cognition is more pro-
nounced in children than in adults.7 In the present study we 
systematically collected and meta-analyzed available quantita-
tive information on the presence, severity and nature of cogni-
tive impairment in children and adults with MMV and its deter-
minants, in particular cerebral perfusion. Furthermore, we aimed 
to determine the effect of surgical intervention on cognition. 
Methods
For the conduction of this systematic review we followed the 
meta-analysis of observational studies in epidemiology 
(MOOSE) guidelines.8
Search strategy and selection criteria
We searched Ovid Medline and Embase for publications of 
studies describing cognitive function in patients with MMV 
published between January 1, 1969 (the year the disorder was 
given its name) and October 4, 2016 (see online Supplementary 
for Syntax). No limits were set for languages; native speakers 
translated papers that were written in other languages than 
English, German, or French. Titles and abstracts were scanned 
and papers were included on the basis of full text by two au-
thors independently (A.K. and C.J.M.K.); disagreement was re-
solved by consensus. Additional studies were included from the 
reference lists of included studies. We included studies report-
ing cognitive or intellectual functioning in children and adults 
that allowed analysis of quantitative data on group level (i.e., 
intelligence quotient [IQ] scores) of at least five patients. If au-
thors reported neuropsychological assessment without provid-
ing raw neuropsychological data, we contacted them for addi-
tional data. In case of (suspected) overlap between study co-
horts, we included the study with the largest sample size with 
information on the proportion of patients with impaired cogni-
tion. In case individual patient data were provided, we exclud-
ed patients without quantitative cognitive data.
Data extraction
Three authors (A.K. all papers; C.J.M.K. and E.B. half of the 
studies each) independently extracted data from selected pa-
pers. Disagreements were solved by consensus. Of the authors 
from 13 publications who were approached for additional data, 
one provided baseline characteristics and scores of neuropsy-
chological tests,9 five could not provide additional information, 
and seven authors did not respond. The risk of bias was evalu-
ated by one author (A.K.) using the Newcastle-Ottawa scale 
adapted for cross-sectional studies (see online Supplementary 
for the Risk Assessment).10
We collected the following study characteristics: study de-
sign; midyear of study; in- and exclusion criteria; number of 
patients with MMD or moyamoya syndrome (MMS, known as-
sociated disease);1 mean age and duration of symptoms (at 
time of diagnosis; presentation; neuropsychological assess-
ment, operation, inclusion or not specified); proportion of fe-
males; ethnicity (Asian, Caucasian, Hispanic, African, and Afro-
American, according to the definition provided by the authors, 
or—if not provided—by country of publication); site of clinical 
stroke or TIA (uni- or bilateral); application of diagnostic crite-
ria for MMV;1 site of vasculopathy; and site of (silent) stroke on 
imaging; and results of CBF and cerebrovascular reserve (CVR) 
studies. We divided presenting symptoms into four categories 
depending on the information provided by the authors: (1) 
ischemic stroke only; (2) TIA(s) only; (3) hemorrhage; or (4) 
other symptoms. We collected information on the level of edu-
cation and occupation. In studies that provided longitudinal 
assessment of cognitive functioning, data were also collected 
for the second time-point, including the type of revasculariza-
tion in surgically treated patients. 
From the neuropsychological assessments we extracted the 
following data: mean full-scale intelligent quotient (FSIQ), de-
velopmental quotient (DQ) (pooled with FSIQ as IQ); verbal intel-
ligent quotient (VIQ); performance intelligent quotient (PIQ); raw 
or standardized z-scores of cognitive tests; and the proportion of 
patients with cognitive impairment overall and per cognitive do-
main (Supplementary Table 1 summarizes the specific neuropsy-
chological tests applied by each study). For studies that did not 
provide the proportion of patients with cognitive impairment, we 
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calculated the proportion based on published normative data if 
possible. For DQ (a ratio calculated by dividing the mental devel-
opmental age with the chronological age) we appointed to have 
the same norm sample as (FS)IQ, unless otherwise specified.11 
Cognitive test results derived from neuropsychological evalua-
tion were grouped into six predefined cognitive domains accord-
ing to standard neuropsychological practice specified in Lezak: 
intelligence, memory, processing speed, attention and executive 
functions, visual perception and construction, and language 
(Supplementary Table 2).12 In studies that provided results of 
multiple cognitive tests investigating the same domain, we de-
termined the mean score and, if possible, calculated the mean z-
scores and standard deviations (SDs) for the domain. A z-score is 
a standardized score which entails the number of SDs that an 
individual test result differs from the mean score in healthy con-
trols, thereby indicating the relative location of a measurement 
within its distribution.13 
Data analysis
To assess the presence of cognitive impairment, we determined 
the median proportion of patients with cognitive impairment. 
Cognitive impairment was defined according to the authors’ 
criteria, or as a cognitive score (overall, or on a specific domain, 
or on at least two tests) deviating more than 1.5 SD from the 
population mean, or IQ <85. To assess the severity of the im-
pairment, we calculated the median cognitive scores of the 
various cognitive tests. To determine whether mean age, eth-
nicity, sex, mean duration of symptoms, and presenting symp-
toms were determinants of cognitive impairment, we per-
formed linear regression analysis weighted by the inverse stan-
dard error of the proportion of patients with impaired cogni-
tion. Due to lack of data, this could not be performed for other 
patients’ characteristics. We qualitatively determined the re-
ported association between frontal CBF and CVR and cognitive 
impairment as reported by the authors.
In studies that provided longitudinal assessment of cognitive 
function, we determined whether cognitive functions im-
proved, deteriorated or remained stable over time. For intelli-
gence, we used a cut-off point of more than 10 points differ-
ences of IQ scores at follow-up. For cognitive domains, change 
over time was categorized according to the criteria provided by 
the authors. 
Results
After screening 299 studies (66 studies were screened on full 
text), we included 17 studies reporting cognitive function in a 
total of 434 patients (Figure 1). Eleven studies reported on 281 
children and six studies on 153 adults. Tables 1 and 2 and Sup-
plementary Tables 3 and 4 summarize study and disease char-
acteristics and neuropsychological test results.4,6,9,14-27 Four 
studies reported on cerebral hemodynamic measures in relation 
to cognitive functions.4,9,17,21 Nine studies reported longitudinal 
assessment of cognitive function over time, eight of which 
provided data after surgical treatment in children; one after 
conservative treatment in adults (Table 2 and Supplementary 
Table 5).4,15-20,22,23 Study quality varied between three and six 
out of seven: three studies had a total score of 3;4,21,22 five 
studies a score of 4;16,18-20,23 five studies a score of 5;6,9,17,25,27 
and four studies a score of 6.14,15,24,26 The most important rea-
sons for studies having a risk of bias were: sample size <30 pa-
tients (65%) and no information on whether patients were in-
cluded consecutively (87%) (Supplementary Table 6). 
Children
In the 11 studies reporting on children, median age of the study 
cohorts was 9.4 years (range, 5.9 to 13.9); the median percent-
age females 55% (range, 33% to 75%; 10 studies, 268 pa-
tients). All studies except one14 described Asian cohorts of 
which nine were Japanese. Two studies described the criteria 
they used for the diagnosis of MMV: confirmation by angio-
Figure 1. Flowchart. 
17 Studies reported neurocognitive functions at baseline
11 Studies reported neurocognitive functions in children
8 Studies reported  pre- and postoperative cognitive results
6 Studies reported neurocognitive functions in adults
1 Study reported cognitive results at follow-up
452 Articles identied from PubMed and Embase searches
(January 1969 to October 4th 2016)
299 Records after removing duplicates
62 Articles screened on full text
156 Excluded based on title
4 Articles selected
from references,
related articles and
citation lists of the
selected articles
49 Did not meet the inclusion
criteria/additional data could
not be obtained/had 
overlapping cohorts
81 Excluded based on abstract
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graphic evidence of moyamoya collaterals and stenosis in one 
study14 and according to Sato et al.20 in the other. One paper 
reported the inclusion of patients with MMS (n=20).14 Present-
ing symptoms were reported in 10 studies (216 children). The 
median proportion of children presenting with ischemic stroke 
was 31% (range, 0% to 60%; nine studies, 166 patients), and 
with TIA only 69% (range, 40% to 100%; nine studies, 166 pa-
tients).4,6,14,16-18,20-22 Presentation with hemorrhage was rare (one 
patient in 166 children in nine studies). One study (50 patients) 
did not report symptoms that could be classified according to 
our predefined categories.19 
The median duration of symptoms was 27.0 months (range, 
12.6 to 57.8). We found no information on school performance 
or the presence of depression among the pediatric studies. 
Cognitive impairment 
The median proportion of children with cognitive impairment 
overall was 30% (range, 13% to 67%; seven studies, 133 pa-
tients) (Figure 2) with a median IQ score of 101 (range, 71 to 
107).4,6,17-21 In the included 11 studies, the median IQ score was 
98 (range, 71 to 107),4,6,14-22 median VIQ score was 97 (range, 77 
to 108; seven studies, 170 children),4,6,14,15,18,20,22 and median PIQ 
score was 100 (range, 89 to 109; six studies, 163 chil-
dren).4,6,14,15,18,22 Three studies reported on specific cognitive do-
mains.6,14,15 Memory was affected in 15% of patients (one study, 
13 patients).6 Eight percent of the patients had impairment in 
processing speed and attention and executive functions, and 
18% in the visual perception and construction domain (one 
study, 13 patients).6 The median z-score for memory was –0.39 
(range, –0.85 to 0.45; three studies, 108 children)6,14,15 and for 
processing speed –0.43 (range, –0.86 to 0.00; two studies, 43 
children).6,14 One study (13 patients) assessed additional domains 
with mean z-scores of 0.50 for attention and executive function; 
and –0.53 for visual perception and construction.6
We found no association between mean age (B=–0.014; 
95% confidence interval [CI], –0.112 to 0.083; P=0.723); type 
of presenting symptom (for infarction [B=–0.002; 95% CI, 
–0.017 to 0.013; P=0.672] and for TIA [B=–0.002; 95% CI, 
–0.013 to 0.017; P=0.672); mean duration of symptoms 
(B=0.000; 95% CI, –0.016 to 0.016; P=0.945); and proportion 
of females (B=–0.005; 95% CI, –0.025 to 0.014; P=0.508), and 
the proportion of patients with cognitive impairment (Supple-
mentary Table 7).4,6,18,20,21
Cerebral blood flow 
Three studies investigated the relation between CBF (xenon-en-
hanced computed tomography [CT]4 or single photon emission 
CT [SPECT])17 and IQ scores.21 In one study, patients with a lower St
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IQ showed a tendency for a more marked depression of mean 
CBF than those with a normal IQ (quantitative analysis not pro-
vided).4 Another study reported a marked depression of CBF 
(qualitatively determined) in the frontal lobes in seven out of 
nine patients, all having normal IQ scores.17 The third study re-
ported no relation between abnormal patterns of CBF and IQ.21
Longitudinal results
Eight studies (199 patients) evaluated the effect of revascular-
ization surgery on cognitive performances after a median fol-
low-up period of 35.3 months (range, 6.5 to 113).4,15-20,22 All 
eight studies reported IQ and one also assessed memory. Indi-
rect revascularization was performed in 90.5% of the patients, 
direct in 0.5% and combined in 9%. The median proportion of 
children with impaired intelligence pre-operatively was 33% 
(range, 13% to 67%; four studies, 88 children) and at follow-
up after revascularization 35% (range, 13% to 58%; four stud-
ies, 81 children).17-20 In the other four studies proportions of 
children with impaired IQs were not reported post-operatively.
Median scores at follow-up were: for IQ 97 (range, 68 to 
108; six studies, 161 children) with a pre-operative median IQ 
score in these studies of 101 (range, 71 to 107; 170 children); 
for VIQ 97 (range, 82 to 106; four studies, 107 children) with a 
pre-operative median VIQ score of 101 (range, 77 to 108; 107 
children); and for PIQ 102 (range, 100 to 109; three studies, 
100 children) with a pre-operative median PIQ score of 100 
(range, 97 to 109; 100 children). 
Based on available individual patient data, improvement in IQ 
(≥10 points) was observed in a median proportion of 27% of pa-
tients (range, 5.5% to 53%; five studies, 91 children),4,17,19,20,22 no 
change in 56% (range, 40% to 89%; four studies, 76 children) 
and deterioration in 15% (range, 5.5% to 25%; four studies, 76 
children). Improvement in VIQ was seen in 20% (range, 13% to 
29%; three studies, 37 children),4,20,22 no change in 65% (57% 
and 73%; two studies, 22 children) and deterioration in 13.5% 
(13% and 14%; two studies, 22 children). PIQ scores improved in 
63.5% (60% and 67%; two studies, 30 patients), remained sta-
ble in 20% (one study, 15 patients) and deteriorated in 13% (one 
study, 15 patients).4,22 Memory function improved after surgery 
(pre-operative z-score 0.45; after surgery 0.77).15 One study in 
which 18 out of the 38 patients were operated on (five com-
bined, 13 indirect) reported no improvement of IQ after revascu-
larization (no quantitative data available).16
Adults
In the six studies reporting on adults, median age was 40.1 
years (range, 36.6 to 43.7) and the median percentage of fe-
males 63% (range, 46% to 74%).9,23-27 Of a total of 153 pa-
Table 2. Longitudinal neuropsychological test performances
Study FU period (mo)
Impairment overall (A/B) 
(%)*
Improved (%) Stable (%) Deteriorated (%)
Lee et al. (2011)15† 19‡ 
(5–46)
- - - -
Imaizumi et al. (1999)16† >120§ - - - -
Ohtaki et al. (1998)17† 85.2±32.59∥ 
(23–110)
13/13 12 63 25
Matsushima et al. (1997)18† 113‡ 15/20 - - –
Matsushima et al. (1991)19† 26.2±14.7‡ 
(7–58)
50/49 27 49 24
Sato et al. (1990)20† 44.4±26.3¶ 
(4–99)
67/58 PIQ 11
VIQ 29
DQ 0
PIQ 78
VIQ 57
DQ 100
PIQ 11 
VIQ 14 
DQ 0
Ibayashi et al. (1985)22† 6.5±4.9‡ 
(1–17)
- FSIQ 47 
VIQ 20
PIQ 60
- -
Ishii et al. (1984)4† 6–68‡ 22/- FSIQ 53
VIQ 13
PIQ 67
FSIQ 40
VIQ 73
PIQ 20
FSIQ 6
VIQ 13
PIQ 13
Su et al. (2013)23** 24∥ 0/100 0 0 100
Values are presented as median (range), mean±standard deviation (range), or range.
FU, follow-up; PIQ, performal intelligence quotient; VIQ, verbal intelligence quotient; DQ, developmental quotient; FSIQ, full-scale intelligent quotient.
*A/B, prior neuropsychological test result/longitudinal neuropsychological test result; †Studies reporting results in children; ‡FU period defined as time of oper-
ation to NPA; §FU period defined as time from onset of disease to neurospychological assessment; ‖FU period defined as time of NPA to NPA; ¶FU period un-
specified; **Studies reporting results in adults.
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tients, 87 were Asian (57%), 56 Caucasian (37%), and 10 had 
another ethnicity (7%). The median proportion of adults pre-
senting with ischemic stroke was 27% (range, 0% to 72%; five 
studies, 117 patients), TIA only 17% (range, 0% to 54%; five 
studies, 117 patients), hemorrhage 3% (range, 0% to 100%; 
five studies, 117 patients), and 19% (range, 0% to 57%; five 
studies, 117 patients) had other symptoms.9,23,25-27 The median 
duration of symptoms at assessment or inclusion was 18.6 
months (1.2 and 36.1 months; two studies). 
Cognitive impairment 
The median proportion of patients with cognitive impairment 
was 31% (range, 0% to 69%; five studies, 127 patients).9,23-25,27 
In the four studies investigating cognition by means of a neuro-
psychological test battery, the median proportion with impaired 
cognition on one or more of the reported domains was 42.5% 
(range, 30% to 69%).9,24,25,27 The median IQ score was 95 (range, 
94 to 99; three studies, 88 patients);24,25,27 median VIQ score was 
94 and median PIQ score 93 (two studies, 59 patients).
Four studies (101 patients) reported on specific cognitive do-
mains.9,24,25,27 The median proportion of patients with impaired 
memory was 37% (range, 7% to 54%), impaired processing 
speed 28% (range, 21% to 39%), impaired attention and execu-
tive functions 37% (range, 19% to 54%), impaired visual per-
ception and construction 23% (range, 22% to 29%), and im-
paired language 35% (range, 20% to 40%).9,24,25,27 The median 
z-scores (three studies, 78 patients) were: for memory –0.4 
(range, –1.1 to –0.2), for processing speed –0.9 (range, –1.7 to 
–0.8), for attention and executive function –0.9 (range, –0.95 to 
–0.4), for visual perception and construction –0.4 (range, –0.5 to 
–0.2), and for language –0.6 (range, –0.8 to –0.15). One study of 
patients with an intraventricular hemorrhage (IVH) showed a 
mean score within the normal range (27.4±1.2 [range, 26 to 29]) 
on the Montreal Cognitive Assessment (MoCA).23
We found no association between mean age (B=–0.044; 
95% CI, –0.184 to 0.096; P=0.387) or proportion of females 
(B=0.011; 95% CI, –0.031 to 0.053; P=0.460) and cognitive 
impairment (Supplementary Table 7). Analysis of the associa-
tion of type of presenting symptom and cognitive impairment 
was not possible, because of lack of data categorized according 
to our predefined classification.
The mean duration of education was 12.1±3.1 years (three 
studies, 91 patients).24-26 In a series of 26 patients from one 
study, nine finished college or a higher-level education, five 
primary school or less, and 12 middle school.23 Another study 
of 36 patients reported that 25 participated in a full-time job, 
Figure 2. Mean intelligence quotient (IQ) with 95% confidence interval (CI) in children (11 studies, 281 children) ordered by mean age (mean summary IQ, 
95.5; 95% CI, 86.7 to 104.2). The blue vertical line represents the mean IQ in the average population. 
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five were unemployed and five were homemakers; one patient 
had retired.24
Cerebral blood flow studies
One study reported a correlation of the apparent diffusion co-
efficient (ADC) in normal appearing frontal white matter on 
diffusion weighted imaging with CVR on perfusion magnetic 
resonance imaging and executive functions (Spearman coeffi-
cient, –0.46; P=0.01).9 Elevation of ADC was significantly cor-
related with executive dysfunction (area under the curve for 
cognitive impairment, 0.85; 95% CI, 0.59 to 1.16; P=0.032). 
Longitudinal results
In the study assessing cognitive impairment in patients with 
solely IVH, all patients had normal MoCA scores at baseline 
(mean MoCA score 27.4±1.2 [range, 26 to 39]) and mild cogni-
tive impairments after a mean follow-up of 24 months (mean 
MoCA score 18.7±1.3 [range, 16 to 21]) without treatment.23 
Discussion
Our systematic review shows that around 30% of children and 
of adults have cognitive impairment. When assessed on a 
group level, median IQ scores are within the normal range in 
both children and adults. Information on specific domains of 
cognitive function is limited, with relatively modest impair-
ments in memory and processing speed observed in children, 
and modest to large impairments across various cognitive do-
mains in adults. 
Since there was not a large discrepancy between VIQ and PIQ, 
total IQ scores provide a reliable insight in cognitive functioning 
in children. Longitudinal results in children showed that IQ 
scores on a group level remained within normal limits over time. 
In adults, longitudinal studies of neuropsychological assessments 
other than with a screening test have not been performed. 
In a previous review, the authors concluded that cognition is 
affected more frequently in children than in adults, reporting in-
telligence to be impaired in children, and executive functions in 
adults.7 However, our systematic review and meta-analysis show 
that in adults the proportion of patients with impairment of 
cognitive function is as large as in children. In comparison with 
this aforementioned review, we included five additional studies 
on children6,14,15,21,22 and four recent studies on adults;9,23,26,27 and 
excluded studies without quantitative data. Although the high-
est median percentage of impaired function was found in the 
domain attention and executive functions, we found similar pro-
portions of patients with impairment for the other cognitive do-
mains. In children, other domains than intelligence were investi-
gated in only three studies. Patients with a normal intelligence 
may show selective cognitive impairment in other cognitive do-
mains. Therefore, extensive neuropsychological evaluation is of 
great importance, also in children who generally show a diffusely 
impaired cognitive profile in case of cognitive deterioration be-
cause their brain is still developing. 
It remains uncertain if the neurocognitive profile of patients 
with MMS differs from that in patients with MMD, since the 
presence of associated diseases was reported in only one study, 
which did not demonstrate a difference between these groups.14 
We did not find an association between the predefined deter-
minants and the proportion of patients with cognitive impair-
ment, probably due to the limited data available. Some of the 
included studies suggested that age at onset4,6,22 and longer du-
ration of disease were6 associated with cognitive dysfunction, 
however we could not confirm these associations in our meta-
analysis. Previous studies were small including 13 to 20 patients 
and observed associations may have been due to chance. Infor-
mation on the determinants of cognitive impairment and its 
course is scarce. The relation between cerebral perfusion and 
cognition in children remains unclear, whereas in adults, a single 
study suggested a relation between diminished perfusion in the 
frontal matter and executive dysfunction. Several studies have 
suggested that (frontal) hypoperfusion, white matter disease and 
infarction are associated with cognitive disturbances.28-31 It re-
mains unclear whether MMV directly affects cognition by 
chronic hypoperfusion, or that cognitive impairment is mainly 
the result of stroke. The observed impaired cognition in patients 
without stroke supports the hypothesis that chronic hypoperfu-
sion is a contributing factor to cognitive impairment in patients 
with MMV.5,6 One study reported that executive dysfunction was 
associated with stroke and white matter lesions and not with 
CVR; however, patients with higher baseline CBF had better cog-
nitive functioning.32 Improvement in intelligence and cerebral 
perfusion in children has been observed after revascularization 
surgery,4,17 and for this reason frontal revascularization proce-
dures are performed more often.2,17,33 Whether prevention of 
cognitive decline should be an indication for revascularization 
surgery in patients with MMV remains unclear. Although our re-
view shows that a fair number of patients improved or remained 
stable after revascularization, the quantity of the included data 
is too limited to draw final conclusions.
Although we were able to collect a reasonable amount of 
data on cognitive function in patients with MMV, the review 
was limited by the relatively low number of patients described 
in the individual studies. Information bias could not be avoided, 
given the large heterogeneity of the reported cognitive tests. 
Since little information on patients’ characteristics was avail-
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able, results could be influenced by selection bias and we could 
not control for confounding factors like the presence of silent 
infarction on imaging. Finally, we were not able to perform 
meta-analysis of the relation between CBF and cognition and 
of the effect of revascularization due to the low number and 
heterogeneity of studies. Our review also has strengths. We 
were able to quantify cognitive impairments in MMV. In addi-
tion, we were able to eliminate the risk of selection bias due to 
language since we did not include language restrictions. De-
spite these methodological shortcomings, our results give valu-
able insight in the presence, severity and nature of cognitive 
functions in MMV before and after revascularization, since we 
quantified cognitive impairments in MMV.
Conclusions
Large prospective studies with a standardized neuropsychologi-
cal test battery are needed to determine the severity of cogni-
tive impairment and the domains affected. Information on 
school level and performance, and on work status is also of 
importance, since it reflects function rather than deficits.34 It 
remains to be established whether cognitive outcome can be 
improved by revascularization surgery. 
Supplementary materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2018.01550.
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Supplementary for Syntax 
OVID Medline (PubMed) syntax
(moyamoya OR moya OR moya-moya [Title/Abstract]) AND (cognition OR neurocognitive OR intelligence OR psycho OR executive OR cognitive OR mental OR 
retardation OR memory OR language OR dementia [Title/Abstract]) 
Embase syntax
(moyamoya:ab,ti OR moya:ab,ti OR moya moya:ab,ti) AND (cognition:ab,ti OR neurocognitive:ab,ti OR intelligence:ab,ti OR psycho:ab,ti OR executive:ab,ti OR 
cognitive:ab,ti OR mental:ab,ti OR retardation:ab,ti OR memory:ab,ti OR language:ab,ti OR dementia:ab,ti)
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Supplementary for the Risk Assessment
Newcastle-Ottawa Scale adapted† for cross-sectional studies
 Selection: (Maximum 4 stars)
1) Representativeness of the sample‡
 a) Truly representative of the average in the target population*
 b) Somewhat representative of the average in the target population* 
 c) No description of the derivation of the cohort
2) Sample size§
 a) Justified and satisfactory*
 b) Not justified
3) Selection criteria
 a) Selection criteria were clearly described and consecutive patients were included*
 b) Selection criteria were not clearly described and it was unclear whether consecutive patients were included
4) Ascertainment of the exposure| |
 a) Validated measurement tool* 
 b) Non-validated diagnostic measures (but the tool is available or described), or not all patients were DSA proven*
 c) No description of the diagnostic tool
Outcome: (Maximum 3 stars)
1) Assessment of the outcome (description of cognitive tests applied)¶
 a) Extensive neuropsychological evaluation**
 b) IQ*
 c) Screening test*
 d) No description
2) Quantitative data:
 a) The study reported cognitive or intellectual functioning in children and adults that allowed analysis of quantitative data.*
 b) The study did not report cognitive or intellectual functioning in children and adults that allowed analysis of quantitative data.
DSA, digital subtraction angiography; IQ, intelligence quotient.
The asterisk refers to the the number of stars (* or **) that can be assigned. It's a scoring method but not an actual footnote; †This scale has been adapted by 
the authors from the Newcastle-Ottawa Quality Assessment Scale for cohort studies1 and the scale developed by Herzog et al. (2013)2 to perform a quality 
assessment of cross-sectional studies for the systematic review: ‘Cognitive functions in children and adults with moyamoya vasculopathy: a systematic review 
and meta-analysis.’ Since there were no groups to compare (only patients with moyamoya (no control groups) were reviewed for this systematic review), we 
could not include the section ‘Comparability’; ‡Patients with moyamoya disease or syndrome: 1 star; §Sample size of n≥30: 1 star; | | DSA or magnetic reso-
nance angiography: 1 star; ¶Neuropsychological test battery applied: 2 stars, IQ or screeningtest: 1 star. 
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Supplementary Table 1. Applied cognitive instruments/tests for each study
Study Applied instruments/tests*
Hsu et al. (2014)3† WISC-III or WISC-IV; WAIS-III
POI: Perceptual Organization Index 
WMI: Working Memory Index
PSI: Processing Speed Index
WL1: Immediate Recall of the Word List 
WL2: Delayed Recall of the Word List
WL-recog: Recognition of the Word List 
CFT: Category Fluency Test
JLO: Judgment of Line Orientation
Williams et al. (2012)4† WISC-III or WISC-IV; WAIS-III; WPPSI-III
VCI: Verbal Comprehension Index  
PRI: Perceptual Reasoning Index 
WMI
PSI
Lee et al. (2011)5† KEDI-WISC-R
BGT recall: Bender Gestalt Test
Imaizumi et al. (1999)6† WPPSI; WISC-R; WAIS-R; Tanaka-Bonet Intelligence Test
Tumori-Inage Mental Development Test
Ohtaki et al. (1998)7† WAIS-R; WISC-R
Matsushima et al. (1997)8† WISC
Matsushima et al. (1991)9† WISC; development questionnaires of Tsumori et al.
Sato et al. (1990)10† WISC-R; WIPPSI; Developmental test
BGT
Tagawa et al. (1989)11† WISC
Ibayashi et al. (1985)12† WAIS; Benton's Visual Memory Test
Ishii et al. (1984)13† WISC; WAIS
Lei et al. (2017)14‡ TMT-B (s): Time consumed in the Trail Making Test part B
MES-EX: executive subtests of Memory and Executive Screening
Kazumata et al. (2015)15‡ WAIS-III 
WSCT: Wisconsin Sorting Test
TMT-A/B: Trail Making Test part A and B
CPT: Continuous Performance Test
Stroop test
RST: Reading Span Test
Su et al. (2013)16‡ MoCA: Montreal Cognitive Assessment 
Calviere et al. (2012)17‡ Letter R
Category (animals) fluency test
TMT-A/B
Stroop interference condition
Brixton test
WCST-C/-P: Wisconsin Card Sorting Test number of categories and number of perseverations
Colored dots and word sections of the Stroop test
Verbal fluency tests
Naming and Recognition Test of 80 common objects
Rey figure copy test
Hooper test
Immediate and delayed 16 free and cued recalls
Rey figure recall
Kronenburg et al.  Cognitive Dysfunction in Moyamoya: A Review
https://doi.org/10.5853/jos.2018.015504 http://j-stroke.org
Study Applied instruments/tests*
Festa et al. (2010)18‡ WAIS-III; WASI
Hopkins Verbal Learning Test
California Verbal Learning Test
TMT-A/B 
Boston Naming Test
Animal Fluency
COWAT: Controlled Oral Word Association Test
WCST: Wisconsin Card Sorting Test
Grooved Pegboard Test
Hand Dynometer
Karzmark et al. (2008)19‡ WAIS-R; WAIS-III
California Verbal Learning Test-II
Memory Test-Revised Visual Reproduction subtest
Delis-Kaplan Executive Function System Design Fluency Test
FAS/AN: Letter and Category Fluency Tests
TMT-A/B
Grooved Pegboard
Tactile Form Recognition Test
Boston Naming Test
This table represents the cognitive instruments/tests used in each study separately.
WISC (-R or -III or -IV), Wechsler Intelligence Scale (revised or third or fourth edition); WAIS (-R or -III), Wechsler Adult Intelligence Scale (revised or third edi-
tion); WPPSI (-III), Wechsler Preschool and Primary Scale of Intelligence (third edition); KEDI-WISC-R, Korean Educational Development Institute Wechsler In-
telligence Scale for Children-Revised; WASI, Wechsler Abbreviated Intelligence Scale.
*As reported by the authors; †Studies reporting results in children; ‡Studies reporting results in adults.
Supplementary Table 1. Continued
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Supplementary Table 2. Predefined cognitive domains according to stan-
dard neuropsychological practice specified in Lezak20
Cognitive domain Included test
General intelligence
Crystallised intelli-
gence
Verbal IQ
Similarities (WAIS)
Vocabulary (WAIS)
Information (WAIS)
Comprehension (WAIS)
National Adult Reading Test
Synonyms
Fluid intelligence Performal IQ
Raven Progressive Matrices
Picture Completion (WAIS)
Picture Arrangement (WAIS)
Arithmetic
Category Test
Memory
Working memory Digit Span Forward & Backward
Block Span Forward & Backward
Memory Scanning Test
Brown-Peterson task
Learning & Immedi-
ate memory
Logical Memory Immediate Recall
Visual Reproductions Immediate Recall
Paired Associate Learning Immediate Recall  
(verbal & nonverbal)
Serial Digit Learning
Word List Immediate Recall
(Buschke) Selective Reminding Test Immediate  
Recall
Visual Retention Test Immediate Recall
Object Memory Immediate Recall
Rey Complex Figure Immediate Recall
Auditory Verbal Learning Test Immediate Recall
Serial Learning Test
Word/Picture Recognition Immediate Recall
Spatial Memory Test
California Verbal Learning Test Immediate Recall
Claeson-Dahl Test Immediate Recall
Seashore Tonal Memory Test
Figural Memory Immediate Recall
Iconic Memory
Maze Learning Immediate Recall
Tactual Performance Test Immediate
Prose Recall Immediate Recall
Symbol-Digit Learning Test
Cognitive domain Included test
Learning & Immedi-
ate memory
Babcock paragraph Immediate Recall
East Boston Memory Test Immediate Recall
Delayed memory Logical Memory Delayed Recall
Visual Reproductions Delayed Recall
Word List Delayed Recall
(Buschke) Selective Reminding Test Delayed Recall
Visual Retention Test Delayed Recall
Object Memory Delayed Recall
Cognitive domain Included test
Rey Complex Figure Delayed Recall
Auditory Verbal Learning Test Delayed Recall
Paired Associate Learning Delayed Recall  
(verbal & nonverbal)
Word/Picture recognition delayed
California Verbal Learning Test Delayed Recall
Claeson-Dahl Test Delayed Recall
Figural memory Delayed
Maze Learning Delayed
Tactual Performance Test Delayed Recall
Delayed serial visual/verbal form memory task
Prose Recall Delayed
Babcock paragraph Delayed
East Boston Memory Test Delayed Recall
Logical Memory Delayed Recall
Visual Reproductions Delayed Recall
Word List Delayed Recall
(Buschke) Selective Reminding Test Delayed Recall
Visual Retention Test Delayed Recall
Object Memory Delayed Recall
Included test
Rey Complex Figure Delayed Recall
Auditory Verbal Learning Test Delayed Recall
Paired Associate Learning Delayed Recall  
(verbal & nonverbal)
Word/Picture recognition delayed
California Verbal Learning Test Delayed Recall
Claeson-Dahl Test Delayed Recall
Figural memory Delayed
Maze Learning Delayed
Tactual Performance Test Delayed Recall
Delayed serial visual/verbal form memory task
Prose Recall Delayed
Babcock paragraph Delayed
East Boston Memory Test Delayed Recall
Supplementary Table 2. Continued
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Cognitive domain Included test
Processing speed
Psychomotor effi-
ciency
Digit Symbol Substitution
Symbol Digit Modalities Test
Trailmaking Test A
Grooved Pegboard
Purdue Pegboard
Graded Reaction Time Task
Perceptual Speed
Motor speed Simple reaction time
Fingertapping Test
Finger Oscillation Test
Attention
Visual attention Stroop Color Word Test Part I & II
Facial Recognition Test
Target finding task
Sustained attention Digit Vigilance Test
Quatember & Maly’s Vigilance Test
Divided attention PASAT
Selective attention Stroop Color Word Test Part III
Cognitive domain Included test
Cognitive flexibility Lexical Fluency Task
Category Fluency Task
Trailmaking Test B (also C, D and Color)
Category Test
Concept Shifting Task
Wisconsin Card Sorting Task
Serial subtraction (3s of 7s)
Card Sorting
Perception & Con-
struction
Visual Retention Test Copy
Visual Reproductions Copy
Block Design
Clock Drawing
Rey Complex Figure Copy
Tactual Performance Test Part I
Object Assembly (WAIS)
Embedded Figures
De Renzi Rods
Flicker Fusion
Perception of spaced stimuli
Time judgement
Visual Recognition Threshold
Street Completion
Rosen figure drawing test
Supplementary Table 2. Continued Supplementary Table 2. Continued
Cognitive domain Included test
Language (Boston) Naming Test
Token Test
Boston Diagnostic Aphasia Test Writing Scale
IQ, intelligence quotient; WAIS, Wechsler Adult Intelligence Scale. 
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Supplementary Table 6. Critical appraisal of the included studies
Study Study design
Selection Outcome
Representativeness 
of the sample
Sample 
size
Selection 
criteria
Ascertainment 
of exposure
Assessment 
outcome
Quantitative 
data
Hsu et al. (2014)3* Cross-sectional + + + ++ +
Williams et al. (2012)4* Cross-sectional + + + + ++ +
Lee et al. (2011)5* Cross-sectional + + + + ++ +
Imaizumi et al. (1999)6* Cross-sectional + + + + +
Ohtaki et al. (1998)7* Cross-sectional + + + + +
Matsushima et al. (1997)8* Cross-sectional + + + + +
Matsushima et al. (1991)9* Cross-sectional + + + + +
Sato et al. (1990)10* Cross-sectional + + + + +
Tagawa et al. (1989)11* Cross-sectional + ?† ?† + +
Ibayashi et al. (1985)12* Cross-sectional + ?† ?† + +
Ishii et al. (1984)13* Cross-sectional + + +
Lei et al. (2017)14‡ Cross-sectional + + + + + +
Kazumata et al. (2015)15‡ Cross-sectional + + + ++ +
Su et al. (2013)16‡ Cross-sectional + + + + +
Calviere et al. (2012)17‡ Cross-sectional + + + ++ +
Festa et al. (2010)18‡ Cross-sectional + + + ++ +
Karzmark et al. (2008)19‡ Cross-sectional + + + ++ +
*Studies reporting results in children; †This information could not be extracted by our translators; ‡Studies reporting results in adults.
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